Loading
A phase 1/2 trial of DJI136 in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy is a phase 1/2 interventional study registered as NCT07564401 by Novartis Pharmaceuticals, with 80 participants planned, started 2026-06-16 and due to reach its primary completion in 2031-03-03. Interventions recorded: DJI136. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/